CSTL 株価分析 — CASTLE BIOSCIENCES INC (Healthcare >> Diagnostics & Research)
CSTL に関するよくある質問
CSTLのPER(株価収益率)は?
CASTLE BIOSCIENCES INC(CSTL)は現在PER 179.65倍で取引されています。
CSTLのROE(自己資本利益率)は?
CASTLE BIOSCIENCES INCのROEは-2.78%です。
CSTLの配当利回りは?
CASTLE BIOSCIENCES INCの配当利回りは0.00%です。
CSTLの品質スコア(Quality Score)は?
当社のAIはCSTLの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CSTLは今が買い時ですか?
当社AIのタイミングスコアは100点中96点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CSTLはどのセクターに属しますか?
CASTLE BIOSCIENCES INCはHealthcare >> Diagnostics & Researchセクターに分類されます(NASDAQ市場)
CSTL AI Analysis Summary
Our AI summary for CSTL: CASTLE BIOSCIENCES INC (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 179.65, ROE of -2.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 96/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 28.00
Price
1.21
(4.52%)
Day Change
|
|
|---|
CSTL, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 28.00 |
| PBV / Sector |
1.76 / -29.69
|
| Earning Per Share | -0.44 |
| PE / Sector |
179.65 / 48.18
|
| PEG or PE/Growth / Sector |
-1.42 / 1.64
|
| Average 1M Daily Value |
9.70 M
|
| Average 1W Daily Value |
17.92 M
GREAT
|
| Timing Factors |
|
100% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:41 |
| Symbol | CSTL |
| Name | CASTLE BIOSCIENCES INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 30.33 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 812.54 / 38,081.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 W. Parkwood Ave, Friendswood, TX, United States, 77546
Phone: 866 788 9007
Website: https://castlebiosciences.com
Employees: 942
Description: Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
Google